Breaking News: Cheaper Medications, Better Health Outcomes
In a significant move, the Pharmaceutical Benefits Scheme (PBS) has unveiled its first batch of medications with reduced pricing for 2026, offering hope and relief to many Australians.
The Big News: Expanding Access to Treatment
One of the key highlights is the expanded use of adalimumab, marketed as Humira, to treat juvenile idiopathic arthritis. This medication, already listed for other pediatric immune-mediated inflammatory diseases, works by regulating the immune system and reducing inflammation. With up to 30,100 Australians aged 0-24 potentially living with arthritis, this expanded access is a game-changer.
But here's where it gets controversial...
The subsidy brings down the cost from a staggering $650 per script to a more manageable $25. While this is a welcome change, it raises questions about the affordability of healthcare and the impact of such reductions on the overall healthcare system.
More First-Time Listings, More Hope
Odevixibat, sold as Bylvay, makes its PBS debut as a treatment for progressive familial intrahepatic cholestasis, a rare genetic liver disease primarily affecting children. Similarly, ublituximab, marketed as Briumvi, is now listed for relapsing-remitting multiple sclerosis (RRMS). These first-time listings offer new treatment options and hope for patients and their families.
And this is the part most people miss...
The impact of these listings is significant. For instance, over 14,000 patients used a comparable treatment for RRMS through the PBS in 2024, with a script without subsidy costing a whopping $15,000. The new listings and reduced co-payments make these treatments more accessible and affordable.
A Continuous Effort: RRMS Treatments
This is the second consecutive month that a new RRMS treatment has been listed on the PBS. Following the approval of ocrelizumab, sold as Ocrevus, for adult patients in December, the scheme continues its commitment to improving access to RRMS treatments.
PBS Co-Payment Reductions
As of 1 January 2026, the maximum cost of PBS medicines has been reduced from $31.60 to $25, with the concessional co-payment remaining at $7.70 until 2030. This move is part of a broader strategy to make essential medications more affordable for all Australians.
Join the conversation below and share your thoughts on these developments. Do you think these changes will have a significant impact on patient outcomes? Are there any potential challenges or benefits you can foresee? We'd love to hear your insights and opinions!
